SLC40A1抗体;SLC40A1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P13408(SLC40A1 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P13408(SLC40A1 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

The SLC40A1 antibody targets the solute carrier family 40 member 1 (SLC40A1) protein, also known as ferroportin, a critical iron exporter responsible for cellular iron efflux. Ferroportin regulates systemic iron homeostasis by facilitating iron release from enterocytes, macrophages, and hepatocytes into the bloodstream. Dysregulation of ferroportin function is linked to iron metabolism disorders, such as hemochromatosis type 4B (ferroportin disease), caused by SLC40A1 mutations that impair iron transport or lead to protein mislocalization.

SLC40A1 antibodies are essential tools for studying ferroportin expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate iron-related diseases, including anemia, neurodegenerative disorders, and cancer. Researchers also employ these antibodies to explore how genetic variants affect ferroportin’s role in iron recycling, storage, and systemic distribution.

Clinically, SLC40A1 antibodies aid in diagnosing ferroportin-associated hemochromatosis by identifying abnormal protein expression in tissue samples. Their application extends to drug development, particularly in therapies targeting iron overload or deficiency. By elucidating ferroportin’s interaction with regulatory molecules like hepcidin, these antibodies contribute to understanding iron homeostasis and designing targeted treatments. Overall, SLC40A1 antibodies are pivotal in advancing research and clinical management of iron metabolism disorders.